HIV Treatment and Prevention Agents Immunization Presentation 
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. Zanubrutinib demonstrated sustained efficacy in CLL with del(17p), emphasizing the importance of BTK inhibitors in high-risk hematologic malignancies.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A. 2,3 Hypertension remains a major public health challenge both in the United States and globally.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 2, 2025
These technologies prevent the risk of both hypo- and hyperglycemic episodes, facilitating safer fasting. Role of PCP Counseling for Observers Fasting may present risks to post-metabolic and bariatric surgery (MBS) patients. The guidance is updated every 5 years, with the most recent update published in May 2025.
Pharmacy Times
JUNE 16, 2025
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.
Pharmacy Times
JUNE 23, 2025
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." He was joined by Laura, a patient who began tirzepatide treatment shortly after being diagnosed with T2D.
Pharmacy Times
JULY 21, 2025
Cardiovascular disease risks in HIV patients have evolved with ART, requiring preventive measures like statins and cardiovascular risk scores for effective management. Healthy aging in HIV patients involves addressing accelerated aging, multimorbidity, and geriatric syndromes, emphasizing functional ability and quality of life.
Pharmacy Times
JULY 8, 2025
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. These diseases are caused by a dysregulated mucosal immune response to the intestinal microflora in hosts who are genetically predisposed.
Expert insights. Personalized for you.
Let's personalize your content